Francesca Pavesi

Scopus Publications

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study
Elisabetta Petracci, Francesca Pavesi, Luca Castagna, Patrizia Zappasodi, Cristina Papayannidis, et al.
British Journal of Haematology, 2026
Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia
Matteo Maria Naldini, Gabriele Casirati, Matteo Barcella, Paola Maria Vittoria Rancoita, Andrea Cosentino, et al.
Nature Communications, 2023
Acute myeloid leukemia may be characterized by a fraction of leukemia stem cells (LSCs) that sustain disease propagation eventually leading to relapse. Yet, the contribution of LSCs to early therapy resistance and AML regeneration remains controversial. We prospectively identify LSCs in AML patients and xenografts by single-cell RNA sequencing coupled with functional validation by a microRNA-126 reporter enriching for LSCs. Through nucleophosmin 1 (NPM1) mutation calling or chromosomal monosomy detection in single-cell transcriptomes, we discriminate LSCs from regenerating hematopoiesis, and assess their longitudinal response to chemotherapy. Chemotherapy induced a generalized inflammatory and senescence-associated response. Moreover, we observe heterogeneity within progenitor AML cells, some of which proliferate and differentiate with expression of oxidative-phosphorylation (OxPhos) signatures, while others are OxPhos (low) miR-126 (high) and display enforced stemness and quiescence features. miR-126 (high) LSCs are enriched at diagnosis in chemotherapy-refractory AML and at relapse, and their transcriptional signature robustly stratifies patients for survival in large AML cohorts.
miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease
Carolina Caserta, Silvia Nucera, Matteo Barcella, Grazia Fazio, Matteo Maria Naldini, et al.
Leukemia, 2023
Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up
Maria Teresa Lupo-Stanghellini, Simona Piemontese, Andrea Assanelli, Fabio Serpenti, Sara Mastaglio, et al.
Hemasphere, 2021
Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience
Elisabetta Xue, Francesca Lorentino, Francesca Pavesi, Andrea Assanelli, Jacopo Peccatori, et al.
Leukemia Research, 2021
Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant
Raffaella Greco, Francesca Lorentino, Serena Albanese, Maria Teresa Lupo Stanghellini, Fabio Giglio, et al.
Transplantation and Cellular Therapy, 2021
The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia
Daniela Clerici, Chiara Oltolini, Raffaella Greco, Marco Ripa, Fabio Giglio, et al.
International Journal of Antimicrobial Agents, 2021
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program
Fabio Guolo, Luana Fianchi, Paola Minetto, Marino Clavio, Michele Gottardi, et al.
Blood Cancer Journal, 2020
Secondary acute myeloid leukemia (sAML) poorly responds to conventional treatments and allogeneic stem cell transplantation (HSCT). We evaluated toxicity and efficacy of CPX-351 in 71 elderly patients (median age 66 years) with sAML enrolled in the Italian Named (Compassionate) Use Program. Sixty days treatment-related mortality was 7% (5/71). The response rate at the end of treatment was: CR/CRi in 50/71 patients (70.4%), PR in 6/71 (8.5%), and NR in 10/71 (19.7%). After a median follow-up of 11 months relapse was observed in 10/50 patients (20%) and 12 months cumulative incidence of relapse (CIR) was 23.6%. Median duration of response was not reached. In competing risk analysis, CIR was reduced when HSCT was performed in first CR (12 months CIR of 5% and 37.4%, respectively, for patients receiving (=20) or not (=30) HSCT, p = 0.012). Twelve-months OS was 68.6% (median not reached). In landmark analysis, HSCT in CR1 was the only significant predictor of longer survival (12 months OS of 100 and 70.5%, for patients undergoing or not HSCT in CR1, respectively, p = 0.011). In conclusion, we extend to a real-life setting, the notion that CPX is an effective regimen for high risk AML patients and may improve the results of HSCT.
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub
Rocco Piazza, Vera Magistroni, Sara Redaelli, Mario Mauri, Luca Massimino, et al.
Nature Communications, 2018
SETBP1 variants occur as somatic mutations in several hematological malignancies such as atypical chronic myeloid leukemia and as de novo germline mutations in the Schinzel–Giedion syndrome. Here we show that SETBP1 binds to gDNA in AT-rich promoter regions, causing activation of gene expression through recruitment of a HCF1/KMT2A/PHF8 epigenetic complex. Deletion of two AT-hooks abrogates the binding of SETBP1 to gDNA and impairs target gene upregulation. Genes controlled by SETBP1 such as MECOM are significantly upregulated in leukemias containing SETBP1 mutations. Gene ontology analysis of deregulated SETBP1 target genes indicates that they are also key controllers of visceral organ development and brain morphogenesis. In line with these findings, in utero brain electroporation of mutated SETBP1 causes impairment of mouse neurogenesis with a profound delay in neuronal migration. In summary, this work unveils a SETBP1 function that directly affects gene transcription and clarifies the mechanism operating in myeloid malignancies and in the Schinzel–Giedion syndrome caused by SETBP1 mutations.
Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel)
Chiara Cattaneo, P. Zappasodi, V. Mancini, C. Annaloro, F. Pavesi, et al.
Annals of Hematology, 2016
Elderly patients > 65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programs
Massimo Bernardi, Matteo Carrabba, Carlo Messina, Raffaella Milani, Elisa Sala, et al.
American Journal of Hematology, 2016

Francesca Pavesi

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications